Term
| Cyp2d6 drugs affected(2 class) |
|
Definition
| Antidepressants, Anti-psychotics |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Warfarin, NSAIDs, Phenytoin, Tolbutamide |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Aldehyde Dehydrogenase impairment |
|
Definition
| Causes facial flushing with alcohol |
|
|
Term
| Pseudocholinesterase(Butyrylcholinesterase)impairment |
|
Definition
| Results in prolonged muscle relaxant response to succinylcholine |
|
|
Term
| N-acetyltransferase impairment |
|
Definition
| Associated with higher risk of neurotoxicity in isoniazid |
|
|
Term
| Thiopurine S-methyltransferase |
|
Definition
| Higher risk of hematopoietic toxicity for azathiopurine & 6-mercaptopurine |
|
|
Term
| UDP-glucuronosyl-transferase lower expression |
|
Definition
| Higher risk of toxicity for irinotecan |
|
|
Term
| Glutathione S-transferase |
|
Definition
| Higher risk of toxicity with various anti-cancer drugs |
|
|
Term
|
Definition
| Affects toxicity of anti-cancer drugs, digoxin, and other drugs |
|
|
Term
| Organic Anion transporters |
|
Definition
| Affects statins and methotrexate |
|
|
Term
| Organic cation transporters |
|
Definition
| Therapeutic effect of metformin |
|
|
Term
| Vitamin K epoxide reductase |
|
Definition
|
|
Term
| Thymidylate synthase and methylenetetrahydrofolate reductase |
|
Definition
| Affect methotrexate adverse effects |
|
|
Term
|
Definition
| Gq, increases intracellular calcium, predominate in CNS |
|
|
Term
|
Definition
| Gi opening of K+ channels and reduction in cAMP and predominates in myocardium |
|
|
Term
|
Definition
| Gq, increases intracellular calcium, subtype predominates in exocrine glands, vascular endothelium, & smooth muscle |
|
|
Term
|
Definition
| Gi opening of K+ channels and reduction in cAMP and predominates in CNS |
|
|
Term
|
Definition
| Gq, increases intracellular calcium, predominates in vascular endothelium of cerebral vessels |
|
|
Term
|
Definition
| Gq, increases intracellular calcium, predominates in smooth muscle-including most vascular smooth muscle |
|
|
Term
|
Definition
| Gi opening of K+ channels and reduction in cAMP, inhibitory autoreceptor on pre-synaptic nerve terminals, predominates on platelets, adipocytes, and smooth muscle |
|
|
Term
|
Definition
| through Gs AND elevation of cAMP |
|
|
Term
|
Definition
| predominates on heart and renal tubules |
|
|
Term
|
Definition
| predominates in lung and various types of smooth muscle |
|
|
Term
|
Definition
| predominates in adipocytes |
|
|
Term
| Sympathetic mediated by B1(heart) |
|
Definition
| increased heart rate and force of contraction |
|
|
Term
| Sympathetic mediated by B1 and m3(blood) |
|
Definition
| increased blood flow to skeletal muscle |
|
|
Term
| Sympathetic mediated by a1(skin) |
|
Definition
| decreased blood flow to skin and viscera |
|
|
Term
| Sympathetic mediated by B2(lung) |
|
Definition
| relaxation of bronchiolar smooth muscle |
|
|
Term
| Sympathetic mediated by a1(eyes) |
|
Definition
|
|
Term
| Sympathetic mediated by B2 and a1(sugar) |
|
Definition
| Increased gluconeogenesis and glycogenolysis in liver |
|
|
Term
| Sympathetic mediated by B3(fat) |
|
Definition
| increased lipolysis in fat cells |
|
|
Term
| Sympathetic mediated by B1(kidney) |
|
Definition
| increased renin release from kidney |
|
|
Term
| Parasympathetic mediated by m2(heart) |
|
Definition
| reduced heart rate, minimal effect on force of contraction |
|
|
Term
| Parasympathetic mediated by m3(lung) |
|
Definition
| contraction of bronchiolar smooth muscle |
|
|
Term
| Parasympathetic mediated by m3(eyes) |
|
Definition
| constriction of pupils in eyes and accomadation |
|
|
Term
|
Definition
| short-acting and non-selective direct acting cholinergic agonist |
|
|
Term
|
Definition
| short-acting and selective direct acting cholinergic agonist |
|
|
Term
|
Definition
| long acting, non-selective direct acting cholinergic agonist, primarily for glaucoma |
|
|
Term
|
Definition
| long acting, selective direct acting cholinergic agonist |
|
|
Term
| Direct acting Cholinergic agonist effects |
|
Definition
| Vasodilation, increase in heart rate, eye contraction,stimulate secretion, relax sphinter |
|
|
Term
| Indirect acting cholinergic agonist effects |
|
Definition
| Vasodilation, decrease in heart rate, eye contraction,stimulate secretion, relax sphinter |
|
|
Term
|
Definition
| short acting indirect acting cholinergic agonists |
|
|
Term
|
Definition
| long acting indirect acting cholinergic agonists |
|
|
Term
| Cholinergic antagonists effect |
|
Definition
| Inhibit secretion, relax muscles and contract sphincter, slight tachycardia |
|
|
Term
|
Definition
| primarily used as nasal decon, vasoconstriction, increases systolic and diastolic BP, decreases HR |
|
|
Term
|
Definition
primarily use in OH
vasoconstriction, increases systolic and diastolic BP, decreases HR |
|
|
Term
| a1 adrenoreceptor agonist |
|
Definition
| vasoconstriction, increases systolic and diastolic BP, decreases HR |
|
|
Term
| a2 adrenoreceptor agonist |
|
Definition
| suppresion of sympathetic tone, reduction in blood pressure |
|
|
Term
|
Definition
| a2 adrenoreceptor agonist, primary therapeutic use in hypertension |
|
|
Term
| B1 adrenoreceptor agonist |
|
Definition
| increase inotropic and chronotropic effect on heart, increased cardiac output |
|
|
Term
|
Definition
| B1 adrenoreceptor agonist, primary therapeutic use in acute heart failure |
|
|
Term
| B2 adrenoreceptor agonist |
|
Definition
| relaxation of bronchial smooth muscle, vasodilation and mild increase in heart rate and force of contaction |
|
|
Term
|
Definition
| B2 adrenoreceptor agonist, primary use in asthma and COPD |
|
|
Term
| a1 adrenoreceptor antagonist |
|
Definition
| vasodilation, decreases venous tone, decreases arterial pressure-primarily affects diastolic pressure, relaxes smooth muscles in prostrate, |
|
|
Term
|
Definition
| a1 adrenoreceptor antagonist, primary therapy to prevent urinary retention with hyperplasia of prostate |
|
|
Term
| B1 adrenoreceptor antagonist |
|
Definition
| negative I and C effect(decreases cardiac output), acute effect- increases peripheral resistance, chronic effect is decrease peripheral resistane, leads to decreased BP, suppreses renin release, also reduces intraocular pressue affecting glaucoma |
|
|
Term
|
Definition
| B1 adrenoreceptor antagonist, affects both B receptors so problematic in asthma patients |
|
|
Term
|
Definition
| B1 adrenoreceptor antagonist,more selective than propranolol |
|
|
